Pantoprazole: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 38: | Line 38: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* | * [[Anaphylaxis]] | ||
* SJS/TEN | * [[SJS/TEN]] | ||
* Renal impairment | * Renal impairment | ||
* | * [[Pancreatitis]] | ||
* | * Hepatic impairment | ||
===Common=== | ===Common=== | ||
Latest revision as of 00:55, 21 February 2021
General
- Type: Proton-pump inhibitor
- Dosage Forms:
- Common Trade Names: Protonix, Somac, Forppi, Pantoloc, Pantozol, Pantomed, Zurcal, Zentro, Pan, Controloc, Tecta
Adult Dosing
Upper gastrointestinal bleeding
- 80mg IV x 1; then 8mg/hr OR 80mg IV BID
- Intermittent dosing is comparable to bolus then continuous drip[1]
GERD, Peptic ulcer disease, Esophagitis
- 40mg IV or PO daily
Pediatric Dosing
- <5yo: safety/efficacy not established
- >5yo
- 15 kg to <40 kg: 20 mg PO qDay
- 40 kg or greater: 40 mg PO qDay
Special Populations[2]
- Pregnancy Rating: B
- Lactation:
- Pantoprazole is present in breast milk
- Renal Dosing
- Adult
- No adjustment necessary
- Pediatric
- Not defined
- Adult
- Hepatic Dosing
- Adult
- No adjustment necessary
- Pediatric
- Not defined
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- SJS/TEN
- Renal impairment
- Pancreatitis
- Hepatic impairment
Common
- Headache
- abdominal pain
- nausea/vomiting/diarrhea
- AST/ALT elevation
Pharmacology
- Half-life: 1 hour
- Metabolism: Hepatic - CYP450
- Excretion: Urine/Feces
- Mechanism of Action: inhibits gastric parietal cell H+/K+ ATPase
See Also
References
- ↑ Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-1762. doi:10.1001/jamainternmed.2014.4056
- ↑ Pantoprazole: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.